<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976868</url>
  </required_header>
  <id_info>
    <org_study_id>3328</org_study_id>
    <nct_id>NCT04976868</nct_id>
  </id_info>
  <brief_title>Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis</brief_title>
  <official_title>Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicine Meda Pharmaceutical Information Consultancy (Beijing) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the present multicentre, prospective, non-interventional study (NIS)&#xD;
      is gathering knowledge on the actual use and effectiveness of Elidel® in Chinese patients&#xD;
      with mild to moderate AD affecting sensitive skin areas in routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SCORAD</measure>
    <time_frame>The study ends after the Maintenance Period of at least 3 months allowing certain flexibility to respond to the routine practice. End of Study will be approx. 6 months after the inclusion depending length of the Elidel® Treatment Period.</time_frame>
    <description>The primary objective is to gather on the actual use and effectiveness of Elidel in Chinese patients with mild to moderate AD affecting sensitive skin areasin routine clinical practice.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Pimecrolimus Cream 1% - Elidel®</arm_group_label>
    <description>Elidel® as prescribed within routine clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus 1% Top Cream</intervention_name>
    <description>Elidel® as prescribed within routine clinical practice</description>
    <arm_group_label>Pimecrolimus Cream 1% - Elidel®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese patients at least 2 years old with mild to moderate atopic dermatitis affecting&#xD;
        sensitive skin areas&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of Chinese ethnicity&#xD;
&#xD;
          -  Patients at least 2 years old&#xD;
&#xD;
          -  Signed informed consent from patient and if applicable from parent(s) or legal&#xD;
             guardian(s) in compliance with local requirements&#xD;
&#xD;
          -  Patients with mild to moderate AD and depending on the age:&#xD;
&#xD;
          -  Patients 2-12 years must have:&#xD;
&#xD;
             - SCORAD Index &lt; 50&#xD;
&#xD;
          -  Patients 13 years and older must have:&#xD;
&#xD;
               -  Affecting sensitive skin areas (e.g. face, intertriginous sites, anogenital area)&#xD;
&#xD;
               -  SCORAD Index &lt; 50 and IGA in sensitive skin areas ≤ 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom Elidel® is not recommended accordingly to the Package Insert&#xD;
&#xD;
          -  Patients with severe atopic dermatitis (SCORAD Index ≥ 50 or IGA in sensitive skin &gt;&#xD;
             3)&#xD;
&#xD;
          -  Receiving systemic glucocorticoids, antibiotics, antifungals, immunomodulators,&#xD;
             inhibitors, antihistamines and ultraviolet radiation therapy within the last 4 weeks&#xD;
             before inclusion;&#xD;
&#xD;
          -  Receiving any topical AD-effective drugs within the last 2 weeks before inclusion;&#xD;
&#xD;
          -  Pregnant and/or breastfeeding women&#xD;
&#xD;
          -  Patients or parent(s) / legal guardian (as applicable) that are not able to fulfil&#xD;
             study requirements according to physician's opinion&#xD;
&#xD;
          -  Patients or parent(s) / legal guardian (as applicable) that refuse to participate to&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yang Ping Echo</last_name>
    <phone>010-65188919</phone>
    <phone_ext>8187</phone_ext>
    <email>ping.yang@viatris.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing children's Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Chang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Capital Institute of Pediatrics</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuotao Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiqiang Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's hospital of Chongqing medical university</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hua Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The third affiliated hospital, sun yat-sen university</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Dou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Medical College Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunhua Deng</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

